Literature DB >> 28770707

Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis.

Xiufang Kong1, Lili Ma1, Zongfei Ji1, Zhihui Dong2, Zhigang Zhang3, Jun Hou4, Si Zhang5, Lingying Ma1, Lindi Jiang6.   

Abstract

OBJECTIVES: This study aimed to clarify potential mechanism of IL-6 involved in adventitial fibrosis via adventitial fibroblast in Takayasu arteritis (TAK).
METHODS: Immunohistochemistry and double-labelled immunofluorescence were performed on vascular tissue from patients with TAK and controls. Human aorta adventitial fibroblast (AAF) was cultured and stimulated with interleukine 6 (IL-6)/IL-6 receptor (IL-6R). Real-time PCR, western blot, enzyme-linked immunosorbent assays, chromatin immunoprecipitation (ChIP) and reporter assay were conducted in vitro experiments to determine effect of IL-6/IL-6R on AAF.
RESULTS: The expression of IL-6, IL-6R, collagen I, collagen III, fibronectin, α-smooth muscle actin (α-SMA), and transforming growth factor (TGF-β) in TAK arteries was significantly higher than that in the normal arteries. Co-localisation of α-SMA and IL-6 and a positive correlation between their expression were observed in local lesions. In vitro experiments, collagen I, collagen III, fibronectin, α-SMA, and TGF-β expression increased significantly after stimulation and this fibrogenesis of AAFs was induced in TGF-β-dependent and -independent manners. Additionally, phosphorylation of JAK2, STAT3 and Akt was significantly enhanced both in IL-6/IL-6R-treated AAFs in vitro and in TAK adventitial α-SMA positive cells. When AAFs were pretreated with inhibitors against JAK2, STAT3, and Akt, fibrosis was significantly reduced. Furthermore, IL-6/IL-6R promoted mRNA expression of IL-6 and MCP-1 in AAFs. Finally, according to ChIP and reporter assay results, STAT3 was the main transcriptional factor in the fibrosis of AAFs induced by IL-6/IL-6R.
CONCLUSIONS: IL-6/IL-6R induces fibrogenesis of AAFs via the JAK2/STAT3 and JAK2/Akt pathways, which provides theoretical evidence for IL-6 as a treatment target in TAK.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28770707

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

Review 1.  Wind of Change in the Treatment of Childhood-Onset Takayasu Arteritis: a Systematic Review.

Authors:  Seher Sener; Ozge Basaran; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

2.  The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up.

Authors:  Ying Sun; Xiufang Kong; Xiaomeng Cui; Xiaomin Dai; Lili Ma; Huiyong Chen; Rongyi Chen; Peng Lv; Jiang Lin; Qingrong Huang; Xuejuan Jin; Lindi Jiang
Journal:  Clin Rheumatol       Date:  2020-05-09       Impact factor: 2.980

Review 3.  A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.

Authors:  Upendra Rathore; Darpan Radheshyam Thakare; Pallavi Patro; Vikas Agarwal; Aman Sharma; Durga Prasanna Misra
Journal:  Clin Rheumatol       Date:  2021-11-03       Impact factor: 3.650

4.  Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons.

Authors:  Kai Kang; Yue Sun; Yi Ling Li; Bing Chang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

Review 5.  Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.

Authors:  Haiyan Li; Zongwen Shuai
Journal:  Heart Vessels       Date:  2021-11-08       Impact factor: 2.037

6.  Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib.

Authors:  Xiaojuan Dai; Jinghua Wang; Xiao Zhang; Li Wang; Sifan Wu; Huiyong Chen; Ying Sun; Lili Ma; Lingying Ma; Xiufang Kong; Lindi Jiang
Journal:  J Inflamm Res       Date:  2022-08-03

7.  Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis.

Authors:  Xiufang Kong; Ming Xu; Xiaomeng Cui; Lingying Ma; Huiyong Cheng; Jun Hou; Xiaoning Sun; Lili Ma; Lindi Jiang
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

8.  In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease.

Authors:  Ji Zongfei; Chen Rongyi; Cui Xiaomeng; Ma Lili; Ma Lingying; Kong Xiufang; Dai Xiaomin; Zhang Zhuojun; Chen Huiyong; Sun Ying; Jiang Lindi
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

9.  IL-6 expression helps distinguish Castleman's disease from IgG4-related disease in the lung.

Authors:  Yasuhiro Kinugawa; Takeshi Uehara; Mai Iwaya; Shiho Asaka; Shota Kobayashi; Tomoyuki Nakajima; Masamichi Komatsu; Masanori Yasuo; Hiroshi Yamamoto; Hiroyoshi Ota
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

10.  Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis-A Pilot Study.

Authors:  Maja Stojanovic; Sanvila Raskovic; Vladimir Milivojevic; Rada Miskovic; Ivan Soldatovic; Sanja Stankovic; Ivan Rankovic; Marija Stankovic Stanojevic; Sanja Dragasevic; Miodrag Krstic; Andreas P Diamantopoulos
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.